Business Wire - June 2, 2000
According to Sandra Thurman, White House Director of the Office of National AIDS Policy, the AIDS epidemic in Africa has become a modern scourge of "almost biblical proportions".
Convinced that the global spread of AIDS is reaching catastrophic dimensions, the Clinton administration has formally designated the disease for the first time as a threat to U.S. national security that could topple foreign governments, touch off ethnic wars and undo decades of work in building free-market democracies abroad.
HIV-VAC's vaccine promises to provide a solution to this worldwide pandemic. Not only could it prevent the disease, and also may prevent the onset of AIDS in HIV-positive patients.
HIV-VAC, Inc. is developing the Skinner HIV-VAC AIDS vaccine which is based on a new and very unique approach to neutralizing the AIDS virus. Unlike many other AIDS vaccines under development, the Company believes that the Skinner vaccine has the potential to be effective with the AIDS virus' many mutant forms. This technology is based on a unique intracellular vaccine technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines. This has been under development by Dr. Skinner and his team for the past 10 years at the University of Birmingham, United Kingdom.
The United Nations estimates that there are currently 33.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million. Sales of anti-HIV drugs increased to more than $3 billion last year and could reach $6 billion in coming years.
The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.
CONTACT: HIV-VAC, Inc. Domenic Franco, 877/847-7719
URL: www.stockprofiles.com/hivc www.stockhouse.com/snapshots/hivc Company Web Site: www.hivvac.com
000602
BW000603
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .